Pretreatment with LCK Inhibitors Chemosensitizes Cisplatin-Resistant Endometrioid Ovarian Tumors

Katie Crean-Tate (kkcrean@gmail.com)
Cleveland Clinic https://orcid.org/0000-0003-2690-9063

Chad Braley
Cleveland Clinic Lerner Research Institute

Goutam Dey
Cleveland Clinic Lerner Research Institute

Emily Esakov
Cleveland Clinic Lerner Research Institute

Caner Saygin
Ohio State University Foundation: The Ohio State University

Alexandria Trestan
Cleveland Clinic Lerner Research Institute

Daniel Silver
Cleveland Clinic Lerner Research Institute

Soumya M. Turaga
University of Kansas Medical Center

Elizabeth V. Connor
Cleveland Clinic Lerner Research Institute

Robert Debernardo
Cleveland Clinic

Chad M. Michener
Cleveland Clinic

Peter G. Rose
Cleveland Clinic

Justin Lathia
Cleveland Clinic Lerner Research Institute

Ofer Reizes
Cleveland Clinic Lerner Research Institute

Research

Keywords: Ovarian cancer, platinum resistance, LCK inhibitor, chemosensitization
Abstract

Background: Ovarian cancer is the most fatal gynecologic malignancy in the United States. While chemotherapy is effective in the vast majority of ovarian cancer patients, recurrence and resistance to standard systemic therapy is nearly inevitable. We discovered that CD55 via activation of the non-receptor tyrosine kinase Lymphocyte Cell-Specific Protein-Tyrosine Kinase (LCK) promoted cisplatin resistance. Here, we hypothesized that treating high grade, platinum resistant endometrioid cancer cells with an LCK inhibitor (LCKi) followed by co-treatment with cisplatin would lead to increased cisplatin efficacy. Our objective was to assess clinical outcomes associated with increased LCK expression, test our hypothesis of utilizing LCKi as pre-treatment followed by co-treatment with cisplatin in platinum resistant ovarian cancer in vitro, and evaluate our findings in vivo to assess LCKi applicability as a therapeutic agent.

Results: Kaplan-Meier (KM) plotter data indicated LCK expression is associated with significantly worse median progression-free survival (HR 3.19, p=0.02), and a trend toward decreased overall survival in endometrioid ovarian tumors with elevated LCK expression (HR 2.45, p=0.41). In vitro, cisplatin resistant ovarian endometrioid cells treated first with LCKi followed by combination LCKi-cisplatin treatment showed decreased cell viability and increased apoptosis. Immunoblot studies revealed LCKi led to increased expression of phosphorylated H2A histone family X (-H2AX), a marker for DNA damage. In vivo results demonstrate treatment with LCKi followed by LCKi-cisplatin leads to significantly slowed tumor growth.

Conclusions: We identified a strategy to therapeutically target cisplatin resistant endometrioid ovarian cancer leading to chemosensitization to platinum chemotherapy via treatment with LCKi followed by co-treatment with LCKi-cisplatin.

Background

Gynecologic malignancy is common, with endometrial and ovarian cancers being the most common incident types in the United States. Ovarian cancer is the most fatal gynecologic malignancy in the United States, with only a 48% survival at 5 years after diagnosis(1). Typically, advanced disease in ovarian cancer is treated with cytoreductive surgery and platinum-based chemotherapy. Up to 15% of ovarian cancers have endometrioid subtype histologically(2). Unfortunately, high-grade endometrioid cancers prove difficult to treat due to recurrence and chemoresistance(3). In ovarian cancer, while up to 85% of patients will enter remission with standard treatment of debulking surgery and platinum-taxane chemotherapy, most of these patients will recur(4). In the 15% of patients failing standard therapy, disease persists or progresses within the first six months after chemotherapy, indicating platinum-resistant disease. For those who enter remission, progression to platinum-resistant disease is pervasive(5). The prognosis is particularly poor in those with platinum-resistant disease, with response rates below 20% for subsequent lines of chemotherapy and continued decrease in disease free interval.
with each subsequent therapy(6). Recurrent ovarian cancer is considered incurable, with goals of care aimed at symptom management with alternative regimens of chemotherapy(7). Given the poor prognosis in patients with platinum-resistant disease, identification of chemoresistance pathways is necessary for development of therapies to sensitize resistant ovarian cancer(8).

Endometrioid tumors have previously been shown to exhibit a self-renewing population of cells termed cancer stem cells (CSC). CSCs are associated with both tumor recurrence and chemoresistance in multiple tumor types(9–12). CD55, a membrane complement regulatory protein, has previously been indicated as a useful marker for high grade, resistant tumors in many types of tumor (13–16). CD55 is highly expressed in endometrioid CSCs (13). Saygin et al. determined that patients with endometrioid tumors highly expressing CD55 exhibit a poorer progression free survival compared to patients with tumors with low expression, and that CD55 is highly expressed in platinum-resistant ovarian endometrioid cancer cells. Saygin et al. also showed that CD55 is necessary for maintenance of chemoresistance via activation of the non-receptor tyrosine kinase LCK to enhance cisplatin resistance by inducing DNA repair genes(13). In vitro studies using saracatinib, an investigational drug that inhibits the LCK, showed sensitization of cisplatin resistant endometrioid cells to cisplatin in a CSC population. With inhibition of LCK, DNA repair genes were attenuated and cells showed increased sensitivity to cisplatin(13). Phase I studies of saracatinib utilized in multiple cancer types have indicated an appropriate safety profile, though follow up randomized human trials in ovarian cancer have fallen short in translating the effect into clinical use(17, 18). With our initial results and proposed mechanism of action of chemosensitization, we hypothesized that treating cancer cells first with an LCK inhibitor, followed by co-treatment with an LCK inhibitor and cisplatin, would enhance the chemosensitization effect. Our primary objective was to test this hypothesis in vitro in a cisplatin resistant endometrioid cancer model, followed by in vivo as a proof of concept.

Results

CD55 and LCK expression are associated with poor patient survival

Given the previously described mechanism of CD55 regulation of cisplatin resistance via the LCK pathway, we hypothesized that both increased CD55 and LCK expression would be associated with worse clinical outcomes. We assessed survival outcomes with increased CD55 and LCK expression for endometrioid ovarian cancer using Kaplan-Meier Plotter database (KM Plotter: http://kmplot.com/analysis/). The database was queried for patients of all stages and grades with endometrioid ovarian cancer. CD55 expression is associated with a significantly worse median progression-free survival (HR 2.98, p < 0.05, Fig. 1a) but did not inform median overall survival (HR 6.48, p = 0.055, Fig. 1b). We then assessed survival outcome in LCK expressed endometrioid ovarian tumors. In endometrioid ovarian cancer, LCK expression is associated with significantly worse median progression-free survival (HR 3.19, p = 0.02, Fig. 1c). Overall survival is not significantly different between groups, though a non-significant trend toward decreased survival was seen with HR 2.45 (p = 0.41, Fig. 1d). These
data indicate increased CD55 and LCK expression in endometrioid ovarian cancer correlates with poorer clinical outcomes.

**Pretreatment with LCK inhibitors chemosensitize cisplatin resistant endometrioid cells and increase apoptosis**

In our prior studies, LCK inhibition in the ovarian endometrioid CSC population led to increased cisplatin sensitivity(13). Given that CSCs are known to be a chemoresistant population closely associated with disease recurrence, we theorized that inhibition of the LCK pathway would lead to sensitization of platinum resistant endometrioid cells. To test our hypothesis, we performed *in vitro* cellular proliferation assays in cisplatin resistant ovarian endometrioid cells (CP70) treated with vehicle or the LCK inhibitor (LCKi) saracatinib followed by cisplatin sensitivity with varying concentrations of cisplatin. There was no significant difference with co-treatment of LCKi and cisplatin alone, so we hypothesized that pretreatment with LCKi is required to effectively sensitize these cells to cisplatin. We found that CP70 cells demonstrated significantly decreased proliferation when pretreated with saracatinib and then treated with combination saracatinib-cisplatin (Fig. 2a). We also tested these cells in a Caspase Glo assay to assess for apoptosis. We determined that CP70 cells pretreated with saracatinib followed by cisplatin plus saracatinib increased apoptosis compared to no pretreatment (Fig. 2b). These findings were replicated in HEC1a, a cisplatin resistant endometrioid endometrial cancer model. HEC1a pretreated with saracatinib followed by cisplatin co-treatment with saracatinib exhibited inhibition of cell viability (Fig. 2c) and increased apoptosis (Fig. 2d) compared to vehicle treated cells.

To validate our hypothesis that treatment with LCKi followed by co-treatment with cisplatin leads to decreased proliferation specifically in cisplatin resistant endometrioid cells, we performed a proliferation assay in A2780 cells, the chemo-naive parent cell line of CP70. We found that pretreatment with saracatinib, as well as simultaneous treatment with saracatinib and cisplatin, did not significantly alter the cell viability (Fig. 2e). To validate our hypothesis that saracatinib chemosensitizes these cells via LCK inhibition, we pretreated CP70 cells with an additional LCKi, PP2, followed by cisplatin co-treatment, and found a dose responsive decrease in cell proliferation seen as compared to control groups treated with cisplatin only (Fig. 2f). These data indicate that platinum resistant endometrioid cells pretreated with LCKi followed by co-treatment with LCKi and cisplatin show decreased cell proliferation and increased apoptosis.

**Cisplatin resistant endometrioid cells treated with LCK inhibitors reveal DNA double strand breaks**

To investigate the mechanism by which LCK inhibitors decrease cisplatin resistance, we tested whether LCK inhibitors decrease phosphorylation of LCK in CP70 cells by immunoblot. We found that phosphorylated LCK (pLCK) was significantly reduced when cells are exposed to LCK inhibitors saracatinib and PP2. GAPDH was used as a loading control (Fig. 3a). We tested for DNA double strand breaks by blotting for γH2AX, a histone that is phosphorylated after DNA double strand breaks occur(19, 20). We found an increase in γH2AX in LCK-inhibitor treated cells (Fig. 3b). These data indicate that endometrioid ovarian cancer cells exposed to LCKi demonstrate a decrease in phosphorylated LCK and an increase in DNA double strand breaks.
Treatment with LCK inhibitor followed by co-treatment with cisplatin decreases tumor growth in vivo

Given the *in vitro* findings, we next tested our hypothesis in an *in vivo* model. We injected NOD severe combined immunodeficient (SCID) IL2R gamma (NSG) mice with CP70 cells virally transduced with luciferase and utilized the *in vivo* imaging system (IVIS) to detect tumor growth on a weekly frequency. After injection of tumor cells (day 0), mice were placed in one of two arms: pre-treatment with saracatinib or vehicle via oral gavage three days per week, initiated on day 3. On day 16 when all mice were confirmed to have detectable tumor on IVIS, mice pretreated with saracatinib were injected with cisplatin three times weekly, and mice pretreated with vehicle were randomly assigned to one of four arms: cisplatin, saracatinib, combination cisplatin and saracatinib, or vehicle alone, given three times per week. Mice were then euthanized on day 30 (Fig. 4a). Images presented for each subgroup were taken from the same mouse over time. Mice treated first with vehicle followed by cisplatin, saracatinib, or combination cisplatin and saracatinib all showed a steady increase in tumor burden over time. However, in mice first treated with saracatinib followed by combination cisplatin and saracatinib therapy, tumor growth appeared stable or attenuated (Fig. 4b, c). At the experimental endpoint (Day 30), the vehicle group indicated that tumor growth was statistically similar to cisplatin, saracatinib, and combination cisplatin and saracatinib arms. However, there was a significant reduction in tumor growth seen in the pretreatment saracatinib followed by combination saracatinib-cisplatin arm as compared to vehicle as well as combination only (Fig. 4d). Of note, this data presents tumor growth corrected to baseline, not absolute tumor size, indicating that the rate at which tumor growth is occurring is significantly reduced relative to other treatment groups. These data demonstrate that pretreatment with LCKi followed by LCKi-cisplatin co-treatment leads to decreased tumor burden in cisplatin resistant endometrioid ovarian cancer *in vitro*.

Treatment with LCK inhibitor in vivo leads to decreased pLCK in cisplatin-resistant endometrioid tumors

To further validate the mechanism by which LCK inhibitors decrease cisplatin resistance, we performed immunoblots on the tumors extracted from our *in vivo* study. We found that mice treated with saracatinib or a combination of saracatinib and cisplatin indicated a substantially lower relative expression of pLCK than mice treated only with vehicle or cisplatin. GAPDH was used as a loading control (Fig. 4e, f).

Discussion

Despite most ovarian cancers displaying an excellent initial response to standard chemotherapy, the majority of advanced stage patients recur, with eventual resistance to our most effective chemotherapy agents. This pattern of pervasive relapse and ensuing chemo resistance is the cause for the poor survival rates seen in ovarian cancer today(3, 5, 9). Studies have focused on identifying a targetable pathway promoting chemo resistance in order to reduce recurrence(9–11). Previous studies by Saygin et al(13) identified a novel pathway leading to chemo resistance in endometrioid tumors in which CD55 mediated DNA repair via phosphorylation of LCK. We assessed clinical outcomes associated with LCK expression. We found that endometrioid ovarian cancers highly expressing CD55 indicated worse clinical outcomes, with significant effects in progression free survival (PFS) (HR 2.98, p = 0.04). Given our prior finding that
the CD55/LCK pathway is involved in chemoresistance, we assessed survival in tumors highly expressing LCK. We found that high LCK expression predicted an even more significant effect on PFS with a three-fold increase in survival from 13 months to 34 months in low versus high LCK expressing tumors. This data suggests a clinical benefit to addressing tumors with increased LCK expression, and thus a potential targetable pathway in recurrent ovarian endometrioid tumors.

Standard chemotherapy in ovarian cancer includes a platinum and taxane agent, and survival decreases as response to platinum therapy diminishes. Prior studies have found that cisplatin resistance is seen with multiple pathways, including increased DNA repair enzyme expression and associated reduction in DNA adducts(9, 13, 21). Through LCK inhibition, DNA repair enzyme expression is attenuated, one of the known pathways to cisplatin resistance(13). Given this anticipated initial chemosensitization step, we pursued pretreatment with LCK inhibitors followed by co-treatment with cisplatin and found that this technique was effective in decreasing cancer cell populations and increasing apoptosis in vitro (Fig. 2). We verified the effects of inhibition of LCK on DNA damage and found an increase in DNA adduct formation with LCK inhibition in immunoblot studies (Fig. 3), an indication that targeting this pathway allows platinum therapy to function in a previously cisplatin resistant cell population.

A common challenge in translational research is that while in vitro studies may prove promising, translating this to effective in vivo studies and clinical trials can prove difficult. Saracatinib, an investigational LCKi, has been studied for several cancer types, with mixed results. Studies on safety found appropriate dosing for saracatinib in humans for effective pharmacodynamics while limiting toxicity, indicating this drug would be tolerable in clinical trials(17). While utilizing saracatinib as monotherapy has not proven efficacious, combination therapy has yielded more promising results. In a study combining saracatinib with carboplatin and/or paclitaxel in solid tumors, objective responses were seen in ovarian, breast and skin cancers, with longest response durations seen in patients with ovarian cancer(17). However, a randomized trial further assessed treatment with saracatinib in combination with weekly paclitaxel in platinum-resistant ovarian cancer, and found that co-treatment of saracatinib with weekly paclitaxel did not improve outcomes(18). Of note, the majority of these tumors were serous histology, and patients received only weekly Taxol without platinum in addition to saracatinib. There is no clinical randomized data assessing saracatinib with cisplatin use in platinum resistant patients. We see from this clinical data that saracatinib is well tolerated and may have a role in combination therapy in platinum resistant disease. We tested this hypothesis with a novel administration of saracatinib followed by co-treatment with cisplatin and found a decreased rate of tumor growth in vivo (Fig. 4), identifying a targetable pathway (Fig. 5) and providing a novel therapeutic regimen for platinum resistant ovarian endometrioid carcinoma.

This study's strength lies in the proof of concept findings using both in vitro and in vivo models. Additionally, whereas prior studies focused on a specific cell population, cancer stem cells, this study utilized a more heterogeneous cell population, more closely simulating a typical tumor microenvironment. Further investigation should also be performed in additional histologic types such as serous and clear cell, as well as substitution of cisplatin for co-treatment with carboplatin, a commonly used platinum
agent. Patients with platinum resistant disease have often received multiple lines of chemotherapy previously and would benefit from further treatment options. Given our promising findings, further studies are indicated to pursue LCK inhibitors as an adjunctive therapy to platinum resistant disease in clinical trials.

**Conclusion**

In summary, we identified a targetable pathway for chemosensitization of platinum resistant ovarian endometrioid cancer. We found that pretreatment with LCK inhibitors followed by co-treatment with cisplatin leads to decreased cell viability and increased apoptosis *in vitro*. This is associated with increased DNA adduct formation and significantly reduced tumor growth *in vivo*. Further studies are needed to assess the mechanisms behind the enhanced efficacy of pretreatment, as well as further investigation of LCK inhibitors as adjunctive therapy for platinum resistant endometrioid ovarian carcinoma, including other histological subtypes.

**Methods**

**Cell Culture**

Ovarian endometrioid adenocarcinoma cell lines A2780 (cisplatin sensitive) and its cisplatin resistant daughter cell line CP70 were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum at 37 °C in a humidified atmosphere in 5% CO₂. Cisplatin resistant endometrioid endometrial cancer cell line HEC1a was cultured in modified McCoy’s 5a medium supplemented with 10% heat-inactivated fetal bovine serum, also at similar conditions. Cell lines were obtained from the Cleveland Clinic centralized research core facility, through which cell lines were previously obtained from the American Type Culture Collection (ATCC) and authenticated. At approximately 80% confluence, trypsin (0.25%)/EDTA solution or Accutase was used to lift cells for passaging as needed for continued experiments until passage 10, at which point a fresh allotment of cells was plated. Cisplatin was obtained from Cleveland Clinic Hospital pharmacy, with 1 mg/mL stock solutions stored at room temperature protected from light given its photosensitivity. Saracatinib (AZD0530) was purchased from Selleck Chemicals and 10 μM stock solutions were aliquoted and stored at -20 °C. PP2 (AG1879) was purchased from Selleck Chemicals and 10 μM stock solutions aliquoted and stored at -20 °C.

**Proliferation Assays and Caspase 3/7 Assays**

The appropriate cancer cells for each experiment were pre-treated with saracatinib (1μM), PP2 (10–50 μM), or vehicle (DMSO at similar concentration to drug of interest) for 4 days in T75 flasks. Cells were then plated in 96-well plates at 5,000 cells/well on seeding Day 0, manually counted by hemocytometer using Trypan blue dye exclusion as live cell marker. Cisplatin was then applied the next day at doses of 0–10 μM, with/without saracatinib, PP2 or vehicle, and treatment was ongoing for 4 to 6 days. Measured
proliferation was assessed by CellTiter-Glo (Promega, Southampton, UK) as per manufacturer’s instructions. Percentage survival was normalized to the untreated control for each group.

Caspase 3/7 Assay kit (Promega, Southampton, UK) was utilized to assess apoptosis as per manufacturer’s instructions. This was performed alongside CellTiter-Glo to correct for viable cell density. Relative Caspase activities were normalized to untreated controls in each group, with activity assessed from 30–120 minutes. Three independent experiments were performed at minimum, each with three technical replicates.

**Immunoblotting**

Protein lysates were obtained with cell lysis in 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1% NP-40, 1 mM EGTA, 1% sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM sodium orthovanadate, 1 µg/mL leupeptin, 20 mM NaF and 1 mM PMSF. Protein concentrations were measured with BCA Protein Assay Kit (ThermoFisher Scientific). Protein concentrations from 20–50 µg of total protein were resolved in 10–12% SDS-PAGE and transferred to PVDF membrane. Membranes were incubated overnight at 4 °C with primary antibodies against pLCK (Y394) (1:1000) (R&D Systems), GAPDH (1:1000) (Cell Signaling), and γ-H2AX (1:1000) (Cell Signaling). Secondary anti-mouse or anti-rabbit IgG antibodies conjugated to horse radish peroxidase (HRP) (1:3000) (Cell Signaling) or (1:25,000) (Promega) were used. ECL was then used (Pierce) to visualize immunoreactive bands.

**In vivo Study**

All animal procedures were evaluated and approved prior to initiation by the Institutional Animal Care and Use Committee (IACUC) of the Cleveland Clinic Lerner Research Institute. NOD severe combined immunodeficient (SCID) IL2R gamma (NSG) mice were purchased from the Biological Response Unit (BRU) at the Cleveland Clinic and housed in microisolator units under IACUC protocol #2018−1940. Thirty mice were injected intraperitoneally with 1 million CP70-luciferase virally transduced cells. At the time of injection (day 0), mice were placed in one of two arms, which started day 3: six mice began receiving pre-treatment with saracatinib (Selleck), 25 mg/kg dissolved in 0.5% hydroxypropyl methylcellulose (Sigma-Aldrich), 0.1% Tween 80 (Sigma-Aldrich) via oral gavage three days per week, and 24 mice received vehicle via oral gavage on the same schedule.

Bioluminescence images to detect tumor burden were taken with Xenogen *in vivo* imaging system (IVIS, PerkinElmer) using D-luciferin as previously described(22). Mice received an IP injection of D-luciferin (Goldbio LUCK-1G, 150 mg/kg in 150μL) under inhaled isoflurane anesthesia. Images were analyzed (Living Image Software) and bioluminescence plots of photon flux (photons/second/cm²/steradian) over time were computed for each mouse, with normalization against day 0 signal values. Non-tumor and black backgrounds were also subtracted from each tumor burden region of interest. All images were obtained with a 15 second exposure. On day 16 when all mice were confirmed to have tumor by IVIS, mice pretreated with saracatinib were also treated with cisplatin (2.5 mg/kg, 3 times per week) injected intraperitoneally. On day 16, mice pretreated with vehicle were randomly assigned to one of four arms (6 mice per arm), whereby they were treated with cisplatin, saracatinib, combination cisplatin and
saracatinib, or vehicle alone. Mice were sacrificed on day 30 and all visible tumor was collected for future studies. All mouse procedures were performed under adherence to protocols approved by the Institute Animal Care and Use Committee at the Lerner Research Institute, Cleveland Clinic.

**Statistical Analysis**

Statistical analysis was calculated by one-way ANOVA and two sample t-test, with p-values included. Statistical significance is denoted via * to represent p-value of < 0.05 but > 0.01, ** representing p-value of < 0.01 but > 0.001, and *** representing p-value < 0.001. For proliferation assays, IC50 was calculated using nonparametric values set to nonlinear fit curve as per statistical analysis performed with GraphPad Prism. Survival data was obtained from Kaplan-Meier Plotter (KM Plotter: http://kmplot.com/analysis/) for endometrioid ovarian cancer based on CD55 and LCK mRNA expression. KM Plotter survival data is obtained from an online database collected from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO) and European Genome-phenome Archive (EGA).

**Declarations**

**Ethics approval and consent to participate**

All mouse experiments were performed with adherence to protocols approved by the Institutional Animal Care and Use Committee at the Lerner Research Institute at the Cleveland Clinic (IACUC protocol #2018-1940).

**Consent for publication**

Not applicable.

**Availability of data and materials**

The KM plotter dataset is available at https://kmplot.com/analysis/index.php?p=service&cancer=ovar. The datasets used and analyzed for the current study are available from the corresponding author upon reasonable request.

**Competing interests**

OR has a patent for CD55 as a therapeutic target in cisplatin resistant endometrial cancer pending. CM receives personal fees from Clovis Oncology. The remaining authors have no relevant financial or conflicts of interest to disclose for this work.

**Funding**

Research in the Reizes laboratory is supported by the VeloSano Bike to Cure Impact Award, the Laura J. Fogarty Endowed Chair for Uterine Cancer Research and the Cleveland Clinic Foundation Lerner Institute.

**Authors’ Contributions**
The first author KKCT generated the hypothesis and research question, created study design, executed experiments, analyzed data, and performed primary manuscript authorship. CB and GD contributed to experiment execution and data collection. EE contributed to data organization, analysis, and manuscript editing. CS and EC contributed to hypothesis generation, experiment execution and data organization. AT contributed to experiment execution and data collection. DS contributed to data organization and manuscript editing. ST contributed to experiment execution. RD, CM, and PGR all contributed to data review and manuscript review. JL contributed to hypothesis generation and study design. OR performed significant contributions to hypothesis generation, study design, data review and analysis, and manuscript editing. All authors read and approved the final manuscript.

Acknowledgements:

We acknowledge our gynecologic oncology patients, who continue to be the motivation of our research.

Author's Information

OR and PGR are co-directors of the Center for Research Excellence in Gynecologic Cancer at the Cleveland Clinic.

References

1. Cancer of the Ovary. - Cancer Stat Facts [Internet]. SEER. [cited 2020 May 8]. Available from: https://seer.cancer.gov/statfacts/html/ovary.html.
2. Disaia PJ, Creasman WT, Mannel RS, McMeekin DS, Mutch DG. Clinical Gynecologic Oncology. 9th ed. Philadelphia: Elsevier, 2012.
3. Ozols RF. Treatment goals in ovarian cancer. International Journal of Gynecologic Cancer. 2005;15(Suppl 1):3–11.
4. Corrado G, Salutari V, Palluzzi E, Distefano MG, Scambia G, Ferrandina G. Optimizing treatment in recurrent epithelial ovarian cancer. Expert Rev Anticancer Ther. 2017;17(12):1147–58.
5. Pujade-Lauraine E, Combe P. Recurrent ovarian cancer. Ann Oncol. 2016;27(suppl_1):i63–5.
6. Hanker LC, Loibl S, Burchardt N, Pfisterer J, Meier W, Pujade-Lauraine E, et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Annals of oncology. 2012;23(10):2605–12.
7. Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol. 2007 Oct;14(5):195–208.
8. Monk J, Herzog BJ, Tewari TS. K. Evolution of chemosensitivity and resistance assays as predictors of clinical outcomes in epithelial ovarian cancer patients. Curr Pharm Design. 2016;22(30):4717–28.
9. Wiechert A, Saygin C, Thiagarajan PS, Rao VS, Hale JS, Gupta N, et al. Cisplatin induces stemness in ovarian cancer. Oncotarget. 2016 Apr 20;7(21):30511–22.
10. Kyo S, Maida Y, Inoue M. Stem cells in endometrium and endometrial cancer: accumulating evidence and unresolved questions. Cancer letters. 2011;308(2):123–33.

11. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. nature. 2001;414(6859):105–11.

12. Xiang D, Shigdar S, Bean AG, Bruce M, Yang W, Mathesh M, et al. Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery. Theranostics. 2017 Sep 20;7(17):4071–86.

13. Saygin C, Wiechert A, Rao VS, Alluri R, Connor E, Thiagarajan PS, et al. CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors. J Exp Med. 2017;214(9):2715–32.

14. Meng Z-W, Liu M-C, Hong H-J, Du Q, Chen Y-L. Expression and prognostic value of soluble CD97 and its ligand CD55 in intrahepatic cholangiocarcinoma. Tumor Biology. 2017;39(3):1010428317694319.

15. He Y, Wang W, Xu L, Li L, Liu J, Feng M, et al. Immunohistochemical expression and prognostic significance of CD97 and its ligand DAF in human cervical squamous cell carcinoma. Int J Gynecol Pathol. 2015;34(5):473–9.

16. Liu M, Yang Y-J, Zheng H, Zhong X-R, Wang Y, Wang Z, et al. Membrane-bound complement regulatory proteins are prognostic factors of operable breast cancer treated with adjuvant trastuzumab: a retrospective study. Oncol Rep. 2014 Dec;32(6):2619–27.

17. Kaye S, Aamdal S, Jones R, Freyer G, Pujade-Lauraine E, de Vries EGE, et al. Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours. Br J Cancer. 2012 May 22;106(11):1728–34.

18. McNeish IA, Ledermann JA, Webber L, James L, Kaye SB, Hall M, et al. A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†. Ann Oncol. 2014 Oct;25(10):1988–95.

19. Lj K, Lx Y. Gamma-H2AX - A Novel Biomarker for DNA Double-Strand Breaks [Internet]. In vivo (Athens, Greece). 2008 [cited 2020 May 22]. Available from: https://pubmed.ncbi.nlm.nih.gov/18610740/?from_term=gamma-h2ax&from_pos=2.

20. Kinner A, Wu W, Staudt C, Iliakis G. γ-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic acids research. 2008;36(17):5678–94.

21. Damia G, Broggini M. Platinum Resistance in Ovarian Cancer: Role of DNA Repair. Cancers (Basel). 2019 Jan 20;11(1).

22. Toyoshima M, Tanaka Y, Matumoto M, Yamazaki M, Nagase S, Sagamura K, et al. Generation of a Syngeneic Mouse Model to Study the Intraperitoneal Dissemination of Ovarian Cancer With in Vivo Luciferase Imaging [Internet]. Luminescence: the journal of biological and chemical luminescence. 2009 [cited 2020 May 28]. Available from: https://pubmed.ncbi.nlm.nih.gov/19711487/?from_single_result=PMID%3A+19711487&expanded_search_query=PMID%3A+19711487.

Figures
Figure 1

CD55 and LCK expression are associated with poorer patient survival. Kaplan-Meier progression-free and overall survival curves were obtained from Kaplan-Meier Plotter (KM Plotter: http://kmplot.com/analysis/) for endometrioid ovarian cancer patients who had high versus low tumor mRNA expression of CD55 (A, B) and LCK (C, D) prior to therapy.

A. Progression Free Survival, CD55 Expression

B. Overall Survival, CD55 Expression

C. Progression Free Survival, LCK Expression

D. Overall Survival, LCK Expression
Figure 1

CD55 and LCK expression are associated with poorer patient survival. Kaplan-Meier progression-free and overall survival curves were obtained from Kaplan-Meier Plotter (KM Plotter: http://kmplot.com/analysis/) for endometrioid ovarian cancer patients who had high versus low tumor mRNA expression of CD55 (A, B) and LCK (C, D) prior to therapy.

A. Progression Free Survival, CD55 Expression

B. Overall Survival, CD55 Expression

C. Progression Free Survival, LCK Expression

D. Overall Survival, LCK Expression

Figure 2
LCK inhibitors chemosensitize cisplatin resistant endometrioid cells and increase apoptosis. Cisplatin resistant ovarian endometrioid cells (CP70) were cultured and pretreated with an LCK inhibitor (saracatinib) or vehicle, followed by vehicle or combination LCKi-cisplatin, followed by cell viability assay performed with the CellTiterGlo Assay (A). Caspase 3/7 Assay was then performed to assess apoptosis (B). A second cisplatin resistant endometrioid cell line (HEC1a) was similarly treated and tested with subsequent proliferation and apoptosis assays performed (C, D). Cisplatin sensitive ovarian endometrioid cells (A2780) were cultured and treated according to the aforementioned paradigm (E). An alternative LCK inhibitor (PP2) was utilized for pretreatment in CP70 cells followed by co-treatment with PP2-cisplatin (F). All data represent at minimum three independent experiments with three technical replicates.

Figure 2

LCK inhibitors chemosensitize cisplatin resistant endometrioid cells and increase apoptosis. Cisplatin resistant ovarian endometrioid cells (CP70) were cultured and pretreated with an LCK inhibitor (saracatinib) or vehicle, followed by vehicle or combination LCKi-cisplatin, followed by cell viability assay performed with the CellTiterGlo Assay (A). Caspase 3/7 Assay was then performed to assess apoptosis (B). A second cisplatin resistant endometrioid cell line (HEC1a) was similarly treated and tested with subsequent proliferation and apoptosis assays performed (C, D). Cisplatin sensitive ovarian endometrioid cells (A2780) were cultured and treated according to the aforementioned paradigm (E). An alternative LCK inhibitor (PP2) was utilized for pretreatment in CP70 cells followed by co-treatment with PP2-cisplatin (F). All data represent at minimum three independent experiments with three technical replicates.
Figure 3

Cisplatin resistant endometrioid cells, both in vitro and in vivo, treated with LCK inhibitors indicate decreased pLCK and ovarian endometrioid cells treated with LCK inhibitor indicate increased DNA double strand breaks. Protein lysates from cisplatin resistant ovarian endometrioid cancer cells (CP70) treated with vehicle (DMSO), LCK inhibitor saracatinib (Sar), or PP2 were immunoblotted for pLCK, with GAPDH used as a loading control. Values normalized to vehicle control (A). Protein lysates from ovarian endometrioid cancer cells (TOV112D) treated with varied doses of saracatinib (Sar) were immunoblotted for γH2AX, with GAPDH used as a loading control (B).
Figure 4

Pretreatment with LCK inhibitor followed by LCKi-cisplatin treatment attenuates tumor burden. NSG mice were injected with CP70-luciferase transfected cells followed by pretreatment with LCKi (6 mice) or vehicle (24 mice) for 14 days. LCKi mice were then co-treated with LCKi and cisplatin, and vehicle mice were randomized to further treatment with vehicle, cisplatin, saracatinib, or combination (6 mice per arm) (A). IVIS imaging was obtained on a weekly basis to assess tumor growth (B). IVIS luminescence was
corrected to baseline for each arm and assessed over time (C) and at the experimental endpoint (D). Tumors from NSG mice were extracted, and protein lysates were immunoblotted for expression of pLCK. Values normalized to loading control (E, F).

Figure 4

Pretreatment with LCK inhibitor followed by LCKi-cisplatin treatment attenuates tumor burden. NSG mice were injected with CP70-luciferase transfected cells followed by pretreatment with LCKi (6 mice) or
vehicle (24 mice) for 14 days. LCKi mice were then co-treated with LCKi and cisplatin, and vehicle mice were randomized to further treatment with vehicle, cisplatin, saracatinib, or combination (6 mice per arm) (A). IVIS imaging was obtained on a weekly basis to assess tumor growth (B). IVIS luminescence was corrected to baseline for each arm and assessed over time (C) and at the experimental endpoint (D). Tumors from NSG mice were extracted, and protein lysates were immunoblotted for expression of pLCK. Values normalized to loading control (E, F).

Figure 5

LCK pathway regulates cisplatin resistance in endometrioid tumors. Downstream of CD55, LCK stimulates expression of DNA repair genes, leading to cisplatin resistance. This targetable pathway identifies LCK inhibitors as adjunctive therapy for platinum resistant ovarian endometrioid cancer.
Figure 5

LCK pathway regulates cisplatin resistance in endometrioid tumors. Downstream of CD55, LCK stimulates expression of DNA repair genes, leading to cisplatin resistance. This targetable pathway identifies LCK inhibitors as adjunctive therapy for platinum resistant ovarian endometrioid cancer.